Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IPF Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Combination Product
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 22, 2026, 5:44 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Chronic Allograft Dysfunction
Interventions
STX-100
Biological
Lead sponsor
Stromedix, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced May 22, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 1015550, Pirfenidone
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Atlanta, Georgia • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced May 22, 2026, 5:44 AM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Pirfenidone, Untreated Cohort
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
13,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Plymouth, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
placebo, BIBF 1120
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Barbara, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray
Drug · Other
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hialeah Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced May 22, 2026, 5:44 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
5
States / cities
Baltimore, Maryland • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced May 22, 2026, 5:44 AM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced May 22, 2026, 5:44 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Persistent Cough in IPF, Chronic Cough, IPF
Interventions
RVT-1601, Placebo
Drug
Lead sponsor
Respivant Sciences GmbH
Industry
Eligibility
40 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced May 22, 2026, 5:44 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Idiopathic Interstitial Pneumonias
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Denver, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Garadacimab, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
37
States / cities
Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced May 22, 2026, 5:44 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HEC 68498, Placebo
Drug
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced May 22, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ABBV-142, Placebo for ABBV-142
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Dothan, Alabama • Champaign, Illinois • Hannibal, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 22, 2026, 5:44 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Nerandomilast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 5:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available
View directory record Official record
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 100 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced May 22, 2026, 5:44 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions
iNO
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced May 22, 2026, 5:44 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Diseases, Hypersensitivity Pneumonitis, Idiopathic Interstitial Pneumonias
Interventions
Interstitial Lung Disease
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2035
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced May 22, 2026, 5:44 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
IPF, Reflux
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced May 22, 2026, 5:44 AM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced May 22, 2026, 5:44 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Pulmonary Fibrosis, Lung Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced May 22, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Adjustment Disorder
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 5:44 AM EDT